What is Unicycive Therapeutics Inc's earnings per share (EPS)?

Unicycive Therapeutics Inc (UNCY) reported diluted earnings per share of $-1.67 for fiscal year 2025. This represents a 70.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Unicycive Therapeutics Inc Financials

UNCY

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Unicycive Therapeutics Inc (UNCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI UNCY FY2025 2026-05-12

External financing rather than meaningful revenue is carrying the business, while spending shifts are reshaping losses and liquidity.

Year over year, net loss narrowed by about $10.2M as R&D spending fell by about $10.9M. But operating cash burn still worsened to -$31.3M while SG&A reached $20.4M, showing the company shifted its cost mix rather than improving cash conversion.

The latest year looked more liquid on the surface: current ratio improved to 2.6x and debt-to-equity fell to 0.6x. But that repair came from financing inflows of $46.5M, not operations, which also lifted cash to $29.2M and rebuilt balance-sheet flexibility after earlier strain.

Free cash flow closely tracked operating cash flow, with only $24K of capital spending against -$31.3M of operating cash use. That means this is not an equipment-hungry business; the burn is overwhelmingly tied to research, payroll, and public-company overhead, so cash needs reflect spending choices more than fixed-asset upkeep.

Financial Health Signals

Financial Profile 23/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Unicycive Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Unicycive Therapeutics Inc carries a low D/E ratio of 0.63, meaning only $0.63 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Unicycive Therapeutics Inc's current ratio of 2.59 indicates adequate short-term liquidity, earning a score of 49/100. The company can meet its near-term obligations, though with limited headroom.

Returns

Unicycive Therapeutics Inc generates a -87.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -494.3% the prior year.

Piotroski F-Score Weak

2/9

Unicycive Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.18x

For every $1 of reported earnings, Unicycive Therapeutics Inc generates $1.18 in operating cash flow (-$31.3M OCF vs -$26.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-415.7x

Unicycive Therapeutics Inc earns $-415.7 in operating income for every $1 of interest expense (-$29.5M vs $71K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$29.5M

YoY+8.1%

Unicycive Therapeutics Inc's EBITDA was -$29.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.1% from the prior year.

Net Income

-$26.6M

YoY+27.7%

Unicycive Therapeutics Inc reported -$26.6M in net income in fiscal year 2025. This represents an increase of 27.7% from the prior year.

EPS (Diluted)

$-1.67

YoY+70.4%

Unicycive Therapeutics Inc earned $-1.67 per diluted share (EPS) in fiscal year 2025. This represents an increase of 70.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$31.3M

YoY-9.4%

Unicycive Therapeutics Inc generated -$31.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 9.4% from the prior year.

Cash & Debt

$29.2M

YoY+11.7%

Unicycive Therapeutics Inc held $29.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

22M

YoY+94.3%

Unicycive Therapeutics Inc had 22M shares outstanding in fiscal year 2025. This represents an increase of 94.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-87.9%

YoY+406.3pp

Unicycive Therapeutics Inc's ROE was -87.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 406.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$9.1M

YoY-54.4%

5Y CAGR+55.1%

Unicycive Therapeutics Inc invested $9.1M in research and development in fiscal year 2025. This represents a decrease of 54.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$24K

YoY-66.7%

Unicycive Therapeutics Inc invested $24K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 66.7% from the prior year.

UNCY Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$675K-29.0%	$951K	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.1M-54.4%	$20.0M+55.1%	$12.9M+3.7%	$12.4M+104.5%	$6.1M+499.0%	$1.0M
SG&A Expenses	$20.4M+68.5%	$12.1M+41.6%	$8.5M+2131.6%	$383K+56.3%	$245K+322.4%	$58K
Operating Income	-$29.5M+8.1%	-$32.1M-54.6%	-$20.8M	N/A	-$9.0M	N/A
Interest Expense	$71K0.0%	$71K-13.4%	$82K+1266.7%	$6K-99.0%	$628K+157.4%	$244K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$26.6M+27.7%	-$36.7M-20.2%	-$30.5M	N/A	-$10.0M	N/A
EPS (Diluted)	$-1.67+70.4%	$-5.65	$-1.28-6.7%	$-1.20-39.5%	$-0.86	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.6M	N/A	$3.0M+69.4%	$1.8M-19.4%	$2.2M	N/A	$3.0M-37.4%	$4.9M
SG&A Expenses	$6.8M	N/A	$4.4M-16.0%	$5.2M-10.4%	$5.8M	N/A	$3.2M+26.6%	$2.5M
Operating Income	-$8.4M	N/A	-$7.3M-5.4%	-$7.0M+12.8%	-$8.0M	N/A	-$6.3M+15.5%	-$7.4M
Interest Expense	$15K	N/A	$15K+15.4%	$13K-13.3%	$15K	N/A	$15K-6.3%	$16K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$12.8M	N/A	-$6.0M+6.8%	-$6.4M-1231.1%	$570K	N/A	-$4.1M-141.6%	$9.9M
EPS (Diluted)	$-0.54	N/A	$-0.33+36.5%	$-0.52	$-0.50	N/A	$-0.46+69.3%	$-1.50

UNCY Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$49.1M+55.2%	$31.7M+123.2%	$14.2M+403.6%	$2.8M-85.0%	$18.7M+9088.2%	$204K
Current Assets	$49.0M+58.2%	$30.9M+131.0%	$13.4M+406.8%	$2.6M-85.6%	$18.4M+8925.0%	$204K
Cash & Equivalents	$29.2M+11.7%	$26.1M+169.5%	$9.7M+2032.1%	$455K-97.3%	$16.6M	N/A
Inventory	N/A	N/A	N/A	$2.2M+19.5%	$1.8M	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$18.9M-21.9%	$24.2M+34.6%	$18.0M+448.1%	$3.3M+45.3%	$2.3M-21.4%	$2.9M
Current Liabilities	$18.9M-21.5%	$24.1M+37.6%	$17.5M+433.9%	$3.3M+56.0%	$2.1M-26.8%	$2.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$30.2M+306.4%	$7.4M+295.1%	-$3.8M-717.4%	-$466K-102.8%	$16.5M+717.1%	-$2.7M
Retained Earnings	-$127.8M-26.2%	-$101.3M-56.9%	-$64.5M-89.8%	-$34.0M-113.3%	-$15.9M-169.1%	-$5.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$64.4M+31.1%	$49.1M-2.9%	$50.6M+68.7%	$30.0M+7.3%	$27.9M-11.8%	$31.7M-17.9%	$38.6M-13.7%	$44.7M
Current Assets	$63.5M+29.8%	$49.0M-2.6%	$50.3M+70.3%	$29.5M+8.0%	$27.3M-11.6%	$30.9M-18.0%	$37.7M-14.3%	$44.1M
Cash & Equivalents	$37.4M+28.0%	$29.2M-31.6%	$42.7M+91.2%	$22.3M+12.9%	$19.8M-24.4%	$26.1M-19.2%	$32.3M-22.6%	$41.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$26.7M+41.0%	$18.9M+44.2%	$13.1M-3.2%	$13.6M-18.6%	$16.7M-31.2%	$24.2M-63.5%	$66.4M+11.5%	$59.5M
Current Liabilities	$26.5M+39.9%	$18.9M+44.2%	$13.1M-3.2%	$13.6M-18.6%	$16.7M-30.9%	$24.1M+130.6%	$10.5M-20.1%	$13.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$37.7M+24.9%	$30.2M-19.4%	$37.5M+128.1%	$16.4M+45.8%	$11.3M+51.7%	$7.4M+126.7%	-$27.9M-87.6%	-$14.8M
Retained Earnings	-$140.6M-10.0%	-$127.8M-13.0%	-$113.2M-5.6%	-$107.1M+16.2%	-$127.8M-26.2%	-$101.3M-27.0%	-$79.7M-5.4%	-$75.6M

UNCY Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$31.3M-9.6%	-$28.6M-56.3%	-$18.3M	N/A	-$5.8M	N/A
Capital Expenditures	$24K-66.7%	$72K+500.0%	$12K+500.0%	$2K-93.1%	$29K	N/A
Free Cash Flow	-$31.3M-9.4%	-$28.6M-56.6%	-$18.3M	N/A	-$5.8M	N/A
Investing Cash Flow	-$12.1M-16698.6%	-$72K-500.0%	-$12K-500.0%	-$2K+93.1%	-$29K	N/A
Financing Cash Flow	$46.5M+3.1%	$45.1M+63.7%	$27.5M+5947.3%	-$471K-102.1%	$22.4M	N/A
Dividends Paid	N/A	$1.1M+21.7%	$900K	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$6.2M+22.3%	-$8.0M-34.7%	-$6.0M+29.2%	-$8.4M+5.4%	-$8.9M-36.0%	-$6.5M+29.2%	-$9.3M-46.4%	-$6.3M
Capital Expenditures	$8K	$0-100.0%	$2K-66.7%	$6K-62.5%	$16K-27.3%	$22K-8.3%	$24K+20.0%	$20K
Free Cash Flow	-$6.2M+22.2%	-$8.0M-34.7%	-$6.0M+29.2%	-$8.4M+5.5%	-$8.9M-35.8%	-$6.6M+29.2%	-$9.3M-46.3%	-$6.3M
Investing Cash Flow	-$5.2M+57.3%	-$12.1M-603450.0%	-$2K+66.7%	-$6K+62.5%	-$16K+27.3%	-$22K+8.3%	-$24K-20.0%	-$20K
Financing Cash Flow	$19.6M+196.2%	$6.6M-74.9%	$26.3M+139.7%	$11.0M+331.4%	$2.5M+597.5%	$365K+332.5%	-$157K+80.6%	-$811K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	$0	$0	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

UNCY Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-3077.6%	N/A	N/A	N/A
Net Margin	N/A	N/A	-4525.0%	N/A	N/A	N/A
Return on Equity	-87.9%+406.3pp	-494.3%	N/A	N/A	-60.8%	N/A
Return on Assets	-54.0%+61.9pp	-116.0%+99.3pp	-215.2%	N/A	-53.4%	N/A
Current Ratio	2.59+1.3	1.28+0.5	0.76-0.0	0.81-7.9	8.75+8.7	0.07
Debt-to-Equity	0.63-2.6	3.26+8.0	-4.73+2.3	-7.05-7.2	0.14+1.2	-1.08
FCF Margin	N/A	N/A	-2710.4%	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-34.0%	N/A	-16.0%+23.2pp	-39.2%-44.3pp	5.1%	N/A	N/A	N/A
Return on Assets	-19.9%	N/A	-11.9%+9.6pp	-21.5%-23.5pp	2.0%	N/A	-10.6%-32.7pp	22.1%
Current Ratio	2.40-0.2	2.59-1.2	3.83+1.7	2.18+0.5	1.64+0.4	1.28-2.3	3.61+0.2	3.37
Debt-to-Equity	0.71+0.1	0.63+0.3	0.35-0.5	0.83-0.7	1.48-1.8	3.26+5.6	-2.39+1.6	-4.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Vivani Medical VANI

$98.3M

Alterity Therapeutics Ltd ATHE

$78.6M

OS THERAPIES INCORPORATED OSTX

$77.1M

CEL-SCI Corp CVM

$24.9M

Frequently Asked Questions

Is Unicycive Therapeutics Inc profitable?

No, Unicycive Therapeutics Inc (UNCY) reported a net income of -$26.6M in fiscal year 2025.

What is Unicycive Therapeutics Inc's EBITDA?

Unicycive Therapeutics Inc (UNCY) had EBITDA of -$29.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Unicycive Therapeutics Inc's return on equity (ROE)?

Unicycive Therapeutics Inc (UNCY) has a return on equity of -87.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Unicycive Therapeutics Inc's free cash flow?

Unicycive Therapeutics Inc (UNCY) generated -$31.3M in free cash flow during fiscal year 2025. This represents a -9.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Unicycive Therapeutics Inc's operating cash flow?

Unicycive Therapeutics Inc (UNCY) generated -$31.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Unicycive Therapeutics Inc's total assets?

Unicycive Therapeutics Inc (UNCY) had $49.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Unicycive Therapeutics Inc's capital expenditures?

Unicycive Therapeutics Inc (UNCY) invested $24K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Unicycive Therapeutics Inc spend on research and development?

Unicycive Therapeutics Inc (UNCY) invested $9.1M in research and development during fiscal year 2025.

How many shares does Unicycive Therapeutics Inc have outstanding?

Unicycive Therapeutics Inc (UNCY) had 22M shares outstanding as of fiscal year 2025.

What is Unicycive Therapeutics Inc's current ratio?

Unicycive Therapeutics Inc (UNCY) had a current ratio of 2.59 as of fiscal year 2025, which is generally considered healthy.

What is Unicycive Therapeutics Inc's debt-to-equity ratio?

Unicycive Therapeutics Inc (UNCY) had a debt-to-equity ratio of 0.63 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Unicycive Therapeutics Inc's return on assets (ROA)?

Unicycive Therapeutics Inc (UNCY) had a return on assets of -54.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Unicycive Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Unicycive Therapeutics Inc (UNCY) had $29.2M in cash against an annual operating cash burn of $31.3M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Unicycive Therapeutics Inc's Piotroski F-Score?

Unicycive Therapeutics Inc (UNCY) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Unicycive Therapeutics Inc's earnings high quality?

Unicycive Therapeutics Inc (UNCY) has an earnings quality ratio of 1.18x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Unicycive Therapeutics Inc cover its interest payments?

Unicycive Therapeutics Inc (UNCY) has an interest coverage ratio of -415.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Unicycive Therapeutics Inc?

Unicycive Therapeutics Inc (UNCY) scores 23 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.